Prothena | PRTA - Interest Expense On Debt


Prothena reported $302.58M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics 349.66M 12.86M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Exelixis USD 23.4M 3.9M Sep/2023
Immunic 197K 222K Dec/2025
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Prothena USD 302.58M 47.32M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025